Attached files

file filename
EX-4.4 - EX-4.4 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES E - Apellis Pharmaceuticals, Inc.apls-ex44_92.htm
EX-32.2 - EX-32.2 - Apellis Pharmaceuticals, Inc.apls-ex322_6.htm
EX-32.1 - EX-32.1 - Apellis Pharmaceuticals, Inc.apls-ex321_8.htm
EX-31.2 - EX-31.2 - Apellis Pharmaceuticals, Inc.apls-ex312_11.htm
EX-31.1 - EX-31.1 - Apellis Pharmaceuticals, Inc.apls-ex311_7.htm
EX-23.1 - EX-23.1 - Apellis Pharmaceuticals, Inc.apls-ex231_10.htm
EX-21.1 - EX-21.1 - Apellis Pharmaceuticals, Inc.apls-ex211_9.htm
10-K - 10-K - Apellis Pharmaceuticals, Inc.apls-10k_20191231.htm

Exhibit 23.2

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the incorporation by reference in the following Registration Statements:

 

 

(1)

Registration Statement (Form S-3 No. 333-235830) of Apellis Pharmaceuticals, Inc., and

 

(2)

Registration Statement (Form S-3 No. 333-229091) of Apellis Pharmaceuticals, Inc., and

 

(3)

Registration Statement (Form S-8 No. 333-229876) pertaining to the 2017 Stock Incentive Plan, Inducement Stock Option Award, and 2017 Employee Stock Purchase Plan of Apellis Pharmaceuticals, Inc., and

 

(4)

Registration Statement (Form S-8 No. 333-221528) pertaining to the 2010 Equity Incentive Plan, 2017 Stock Incentive Plan, and 2017 Employee Stock Purchase Plan of Apellis Pharmaceuticals, Inc.;

 

 

of our report dated February 26, 2019, with respect to the consolidated financial statements of Apellis Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Apellis Pharmaceuticals, Inc. for the year ended December 31, 2019.

/s/ Ernst & Young LLP

Boston, Massachusetts

February 27, 2020